Comparative Pharmacology
Head-to-head clinical analysis: BRIELLYN versus NORINYL 1 80 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIELLYN versus NORINYL 1 80 28 DAY.
BRIELLYN vs NORINYL 1+80 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
Combination oral contraceptive containing a progestin (norethindrone) and an estrogen (mestranol). Suppresses gonadotropin (FSH and LH) release via negative feedback, inhibiting ovulation. Also induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
One tablet (1 mg norethindrone / 80 mcg ethinyl estradiol) orally once daily for 28-day cycle without placebo.
None Documented
None Documented
12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment
Norethindrone: terminal elimination half-life of 5.3-10.5 hours; Mestranol (as ethinyl estradiol): terminal half-life of 7-20 hours. Clinically, steady state is achieved after 5-7 days of daily dosing; the half-life supports once-daily dosing for consistent hormonal levels.
Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination
Norethindrone is primarily excreted in urine (approximately 60%) and feces (approximately 40%) as glucuronide and sulfate conjugates. Mestranol is metabolized to ethinyl estradiol; ethinyl estradiol and its metabolites are excreted in urine (40%) and feces (60%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive